BioMarin Pharmaceutical Inc. Q3 FY2025 earnings call

Management Statement and Operational Highlights

• Business Performance: Strong top line growth of 11% year-over-year, driven by Enzyme Therapies and Skeletal Conditions. Raised full year total revenues guidance at the midpoint and reaffirmed VOXZOGO revenue outlook for 2025.
• Strategic Initiatives: Undertaken initiatives to prepare for future growth, including discontinuing research programs that didn't meet criteria. Announced decision to divest ROCTAVIAN to focus on strategic priorities.
• Acquisition Impact: Q3 2025 included a $221 million charge for acquired in-process research and development (IPR&D) related to the Inozyme Pharma acquisition, but underlying revenue performance and operational efficiencies drove increased earnings per share.
• Commercial Update: PALYNZIQ continued strong growth with over 20% growth, and VOXZOGO had 24% year-to-date growth, available in 55 countries. Focus on expanding VOXZOGO to new indications and advancing BMN 333 for achondroplasia.
• R&D Highlights: Pivotal data readout expected for VOXZOGO in hypochondroplasia in first half of 2026, initiation of Phase II/III study for BMN 333 in achondroplasia in first half of 2026, and progress in DMD program with a 10% dystrophin target.

Segment Performance

• Enzyme Therapies: Led by PALYNZIQ, which saw over 20% year-to-date growth. Year-to-date revenue growth across the enzyme therapies portfolio reflects increased new patient starts and strong adherence. The Enzyme Therapies business unit is a $2 billion-plus franchise with continued growth anticipated.
• Skeletal Conditions: VOXZOGO, the treatment for achondroplasia, is expected to generate over $900 million in revenues in 2025, representing 25% growth at the midpoint of the guidance range. VOXZOGO revenue increased 24% year-to-date compared to 2024 and is available in 55 countries. The Skeletal Conditions business unit is focused on expanding VOXZOGO to new indications, including hypochondroplasia, with a pivotal data readout expected in the first half of 2026 and a potential launch in 2027 if data is supportive.

Guidance

• Revenue: Raised full year 2025 total revenue guidance to a lower end of $3.15 billion with midpoint representing double-digit year-over-year growth. Reaffirmed VOXZOGO revenue outlook for 2025 at $900 million to $935 million.
• Operating Margin and EPS: Updated full year 2025 non-GAAP operating margin guidance to 26%-27% and non-GAAP diluted EPS guidance to $3.50-$3.60.
• 2027 Outlook: Shared range of estimates for 2027 revenues, with lower end in line with current consensus and higher end up to $4 billion, but noted many unknowns make specific estimates uncertain.

Risks

• Regulatory and Competitive Risks: Potential competition for VOXZOGO, impact of regulatory decisions, and uncertainties around competitor launches and litigation.
• Pipeline Risks: Uncertainties in clinical trial outcomes, including for BMN 333 and DMD programs.
• Market Risks: Fluctuations in market conditions and impact on revenue projections.

Q: On 2027 guidance, talk about scenarios and why rescinding guidance.

A: Brian Mueller discussed scenarios with lower case (2 competitors) and higher case (delayed competition), noting many unknowns make specific estimates uncertain.

Q: Why VOXZOGO sales down quarter-over-quarter and business development strategy.

A: Brian Mueller cited timing of orders and steady patient addition; Alexander Hardy discussed business development focus on strategic assets.

Q: Qualitative commentary on long-term guidance and capital deployment.

A: Brian Mueller mentioned high single-digit growth for Enzyme Therapies; Alexander Hardy emphasized business development as priority for capital.

Q: BMN 333 PK data and clinical superiority.

A: Greg Friberg discussed free CNP AUC increases and clinical differentiation, but no specific delta mentioned.

Q: Contributions of competition and litigation, DMD program bar.

A: Brian Mueller outlined lower and higher case estimates; Greg Friberg discussed 10% dystrophin target for DMD.

Q: Orphan drug exclusivity, balance sheet capacity.

A: Cristin Hubbard discussed patient switching and adherence; Brian Mueller mentioned $4-5 billion firepower for growth capital.

Q: 2027 scenarios, balance sheet and business development.

A: Brian Mueller explained scenario modeling; Alexander Hardy discussed orphan drug exclusivity petition.